LinkedIn video ad examples
1,395 video ads are live on LinkedIn right now, from 930 companies. Browse real ones, filtered by industry.
- InizioSince 26 Oct 2026
What does it take to show up successfully at congress? At ESMO 2026, Lauren Ince reflects on what sets the strongest congress experiences apart: a clear strategic point of view, carried consistently across every message and every touchpoint. From the journey to congress through to the experience on the show floor, every interaction should reinforce why you’re there and what you want to stand for in oncology. That connected approach is at the heart of Intelligent Congress. #ESMO26 #ReimagineHealth #IntelligentCongress #Oncology
- 4basebioSince 26 Oct 2026
Is plasmid DNA costing you more than you think? It may look affordable on paper, but downstream costs add up fast. Restriction enzymes, extra processing, and purification can all increase spend. Synthetic DNA removes the extras. Fully linearized and ready to use. Discover the difference for yourself. Explore our ready-to-use synthetic DNA catalogue, with plasmid DNA controls included for direct comparison. Start testing from just £100. Request a quote today.
- 4basebioSince 26 Oct 2026
Still think plasmid DNA is your best option? Put synthetic DNA to the test and discover the benefits of cell-free DNA manufacturing. Improved purity. Faster turnaround times. Reduced downstream processing costs. With ready-to-use constructs available for mRNA, saRNA, gene editing, AAV, and DNA reporter applications, you can benchmark synthetic DNA against plasmid DNA in your own workflow. Plasmid DNA controls included for side-by-side comparison. Explore our catalogue and start testing from just £100. Request a quote today.
- Novo NordiskSince 27 Oct 2026
📏 Grandir, ça se mesure ! Comprendre ce qui nous arrive, c’est déjà avancer plus sereinement. 💬 Dans cette interview, Béatrice Demaret, présidente de l’association GRANDIR, rappelle combien la relation de confiance entre l’enfant, ses parents et les professionnels de santé est essentielle. Lorsque le diagnostic et les différentes étapes de la prise en charge sont bien expliqués, l’enfant peut mieux comprendre son parcours, se l’approprier et en devenir pleinement acteur. Parce qu’au-delà du suivi médical, écouter l’enfant, répondre à ses questions et l’accompagner dans la durée font toute la différence. 📏 Et n’oublions pas les bons réflexes pour suivre sa croissance : • de la naissance à 1 an : tous les 3 mois • de 1 à 4 ans : tous les 6 mois • après 4 ans : 1 à 2 fois par an ▶️ Découvrez le témoignage complet de Béatrice Demaret.
- Inuka Coaching (B Corp)Since 27 Oct 2026
Als het budget krapper wordt, is investeren in welzijn vaak het eerste dat moet wijken. Canon Medical deed het tegenovergestelde. Coaching voor hun team leverde 657% rendement op. Hoe? Minder verzuim. Hogere productiviteit. Mensen die bleven.
- Inuka Coaching (B Corp)Since 27 Oct 2026
De meeste bedrijven boeken coaching onder kosten. PVH boekte het onder rendement. 580%, om precies te zijn. Minder verzuim. Hogere productiviteit. Mensen die bleven.
- Atlantia Clinical TrialsSince 24 Oct 2026
Wearables and self-monitoring are shifting care into the home, putting medical devices at the centre of it. Our CCO explains how Atlantia runs the trials behind that shift: full-service design, organisation and execution, in-house recruitment from 40,000+ participants, and full visibility into budgets, recruitment and timelines throughout. We specialise in Class 2 devices, reporting to the FDA and equivalent European bodies.
- ELSANSince 25 Oct 2026
La radiochirurgie franchit une nouvelle étape. Le ZAP-X, installé à l'Hôpital Lariboisière à Paris, permet de traiter des lésions cérébrales sans intervention chirurgicale, avec une précision inédite. Le Dr Nathaniel Scher, oncologue radiothérapeute à l'Institut de Radiothérapie et de Radiochirurgie H.Hartmann, fait partie des équipes qui font vivre cette innovation au quotidien. Dans cette vidéo, il explique le principe de la radiochirurgie : des centaines de microfaisceaux concentrés sur la lésion tumorale, de fortes doses ciblées sur la tumeur, et un cerveau épargné autour. Le patient est allongé, ne ressent rien, et repart le jour même. Derrière la machine, une expertise médicale conjointe : les équipes de l'Institut de Radiothérapie H. Hartmann et de l'AP-HP - oncologues radiothérapeutes, physiciens, neurochirurgiens - travaillent ensemble au service des patients. Un partenariat public-privé que le Dr Scher résume simplement : "Ce qu'on veut, c'est que les patients vivent plus longtemps et surtout qu'ils vivent bien." #Innovation #Radiochirurgie #Oncologie
- ELSANSince 25 Oct 2026
⚜️ Louis XIV souffrait-il d’une maladie rénale ? Une question que l’Histoire ne permet pas de trancher… mais que la médecine peut aujourd’hui éclairer. Au XVIIᵉ siècle, l’insuffisance rénale n’est pas encore identifiée comme une pathologie et les médecins ne disposent d’aucun des outils diagnostiques dont nous bénéficions aujourd’hui. Pourtant, les archives historiques et les récits laissés par les contemporains du Roi Soleil décrivent certains troubles qui interpellent encore les spécialistes. À partir de ces témoignages, le docteur Stanislas Bataille, néphrologue, et Philippe Charlier, anthropologue, se sont intéressés à l’hypothèse d’une maladie rénale chez Louis XIV. Aujourd’hui, la situation a bien changé. 🩺 Les maladies rénales peuvent être dépistées, diagnostiquées et prises en charge, parfois avant même l’apparition de symptômes. Prendre soin de ses reins, c’est aussi penser au dépistage. En cas de facteur de risque ou de question concernant votre santé rénale, parlez-en à un professionnel de santé. 👉 Pour aller plus loin, retrouvez notre article consacré à l’insuffisance rénale, à son diagnostic, à ses symptômes et à ses traitements : https://lnkd.in/dw5638-d #Recherche #HistoireMédicale #SantéRénale
- Atlantia Clinical TrialsSince 24 Oct 2026
You've looked at Atlantia. Here's the actual detail: full visibility into your budget, recruitment and timelines, 40,000+ participants in our recruitment database, and a team that runs your trial end to end. Watch the two-minute breakdown.
- AstraZenecaSince 26 Oct 2026
🫁 Er du lungemediciner eller sundhedsperson med interesse for lungemedicin? Så sæt ✘ i kalenderen fredag d. 9. april 2027. Nye kronikerpakker, sundhedsreformen og fremtidens patientforløb stiller nye krav til det lungemedicinske område. Til Nationalt Lungesymposium 2027 sætter førende danske og internationale eksperter fokus på, hvad det betyder for din kliniske hverdag. 💡 Kom og vær med – vi glæder os til at se dig! 🙌 DK-16795-10-26-R&I
- ArcticZymes Technologies ASASince 26 Oct 2026
Does RNA manufacturing really need more assays, or do we need to get more from the ones we already have? That question came through strongly in our latest podcast, with three different perspectives: 🔬 Mark Dickman called for greater standardisation, particularly around how we measure mRNA integrity and dsRNA. Without it, how meaningful are comparisons between methods, labs or suppliers? 🧬 Francis Combes questioned whether adding more QC assays is really the answer. Could we instead combine critical quality attributes and better connect them to biological outcomes? ⚙️ Ashish Dhir took the conversation upstream, arguing that DNA template quality needs more attention as a determinant of the RNA we ultimately produce. These aren’t separate challenges. They point towards a broader shift in RNA manufacturing: from measuring quality at the end of the process to understanding and controlling it throughout. From advanced analytical tools and improved enzymes to next-generation process controls, where do the experts think the field is heading? 🎧 Listen to the full conversation: https://lnkd.in/eqNkdbyY
- ArcticZymes Technologies ASASince 26 Oct 2026
Does every stage of RNA development need the same level of analytical resolution? Probably not. In our latest discussion on RNA manufacturing, Ashish Dhir, Mark Dickman and Francis Combes explore why a tiered approach to analytics could help teams balance speed, cost and analytical depth. For 5′ cap analysis, rapid or semi-quantitative methods can support process development, while higher-resolution approaches such as LC-MS can provide deeper characterisation later in development. The same trade-offs appear in residual DNA control. qPCR and ddPCR offer powerful detection capabilities, while DNase treatment introduces its own process considerations, from enzyme removal to performance under IVT conditions. The recurring question throughout the conversation: How can we generate analytical data quickly enough to improve the manufacturing process, without compromising the depth of information needed later? 🎧 Explore the full discussion: https://lnkd.in/eqNkdbyY
- AstraZenecaSince 25 Oct 2026
ESMO begins in just a few days, and I’m looking forward to connecting with peers and seeing the latest advances in cancer care from across the R&D and medical community. Ahead of this year’s congress, David Fredrickson and I reflected on 10 years of progress in oncology. We discussed what has had the most impact on cancer care in the past decade and our predictions for the future. Watch until the end to hear our personal lessons learnt over this time! What do you think has been the biggest breakthrough in cancer care in the past decade? #ESMO26
- AttendiSince 23 Oct 2026
𝗢𝗽 𝘄𝗲𝗴 𝗻𝗮𝗮𝗿 𝗠𝗗𝗥: 𝗩𝗲𝗶𝗹𝗶𝗴𝗲 𝗔𝗜 𝗶𝗻 𝗱𝗲 𝘇𝗼𝗿𝗴, 𝘄𝗮𝘁 𝗸𝗼𝗺𝘁 𝗱𝗮𝗮𝗿 𝗮𝗹𝗹𝗲𝗺𝗮𝗮𝗹 𝗯𝗶𝗷 𝗸𝗶𝗷𝗸𝗲𝗻? De adoptie van nieuwe technologie begint bij het vertrouwen hierin. Wanneer een zorgprofessional een gesprek samenvat met de Attendi App, zijn er terechte vragen. Haalt de AI de juiste informatie eruit? Verzint die geen dingen? “De AI werkt goed” is daarbij niet een antwoord dat volstaat. Binnen het MDR-certificeringstraject richten we ons kwaliteitsmanagementsysteem (QMS) in volgens ISO 13485, de internationale norm voor medische hulpmiddelen waaronder medische software. Onderdeel van dit QMS is het technisch dossier. Hierin komen de beoogde toepassing van het product, risicoanalyses, ontwerpkeuzes, testresultaten en klinische onderbouwing samen. Samen moeten deze een controleerbare bewijsketen vormen, zodat het antwoord op deze vragen te verifiëren is en niet slechts wordt beweerd. In het bijbehorende artikel lichten we de punten uit de video verder toe: https://lnkd.in/em2wyuXr 𝘋𝘦 𝘈𝘵𝘵𝘦𝘯𝘥𝘪 𝘈𝘱𝘱 𝘪𝘴 𝘰𝘱 𝘥𝘪𝘵 𝘮𝘰𝘮𝘦𝘯𝘵 𝘨𝘦𝘦𝘯 𝘊𝘌-𝘨𝘦𝘮𝘢𝘳𝘬𝘦𝘦𝘳𝘥 𝘮𝘦𝘥𝘪𝘴𝘤𝘩 𝘩𝘶𝘭𝘱𝘮𝘪𝘥𝘥𝘦𝘭. 𝘋𝘦 𝘔𝘋𝘙 𝘒𝘭𝘢𝘴𝘴𝘦 𝘐𝘐𝘢 𝘤𝘰𝘯𝘧𝘰𝘳𝘮𝘪𝘵𝘦𝘪𝘵𝘴𝘣𝘦𝘰𝘰𝘳𝘥𝘦𝘭𝘪𝘯𝘨 𝘷𝘰𝘰𝘳 𝘩𝘦𝘵 𝘴𝘢𝘮𝘦𝘯𝘷𝘢𝘵𝘵𝘦𝘯 𝘭𝘰𝘰𝘱𝘵 𝘯𝘰𝘨. 𝘝𝘰𝘭𝘨 𝘰𝘯𝘴 𝘰𝘮 𝘰𝘱 𝘥𝘦 𝘩𝘰𝘰𝘨𝘵𝘦 𝘵𝘦 𝘣𝘭𝘪𝘫𝘷𝘦𝘯 𝘷𝘢𝘯 𝘩𝘦𝘵 𝘷𝘦𝘳𝘥𝘦𝘳𝘦 𝘷𝘦𝘳𝘭𝘰𝘰𝘱 𝘷𝘢𝘯 𝘩𝘦𝘵 𝘵𝘳𝘢𝘫𝘦𝘤𝘵.
- Boehringer IngelheimSince 26 Oct 2026
When kidney filters are damaged, a protein called albumin leaks into the urine. This leakage signals widespread inflammation that can damage the heart and brain, increasing the risk of heart attack and stroke. Through Detect the SOS, we're working with partners to make sure this signal doesn't go unnoticed. A simple urine test can help detect this warning sign early. The urine albumin-to-creatinine ratio (uACR) test is a quick, simple way to identify this risk, especially for people living with type 2 diabetes or high blood pressure. 🎥 Watch Dr Neerja Balachander, Vice President for US Clinical Development Medical Affairs, Cardiovascular-Renal-Metabolism at Boehringer Ingelheim, discuss the importance of uACR testing at the Foreign Policy Health Forum. #DetectTheSOS #uACR #HeartHealth #KidneyHealth #GlobalHealth #UNGA81
- Alnylam PharmaceuticalsSince 26 Oct 2026
KardioKosmos, der neue, wissenschaftlich fundierte Podcast rund um die Kardiologie, startet zum Welt-Amyloidose-Tag. Im Fokus der ersten Staffel: die ATTR-Amyloidose. Zum Auftakt erzählt ein Patient von seinem langen Weg bis zur Diagnose.
- DebiopharmSince 26 Oct 2026
🧬 A complementary approach for advanced solid tumors The greatest potential for WEE1 and PKMYT1 inhibition lies in cancers marked by high replication stress and genomic instability, where late cell-cycle checkpoints become critical for survival. This includes advanced solid tumors with specific molecular vulnerabilities, such as alterations that drive uncontrolled cell-cycle progression and checkpoint dependence. Tumor types where these features are commonly observed include: ovarian, breast, lung, colorectal, gastric, and pancreatic cancers, among others. By aligning therapy with underlying biology, this combination strategy aims to focus treatment where it is most likely to be effective. 👇 Learn more about our ongoing clinical trial https://lnkd.in/dfAtKP2M #DNADamageResponse #DDR #PKMYT1 #WEE1 #Oncology #ClinicalTrial #Debiopharm
- Daiichi Sankyo Italia S.p.A.Since 26 Oct 2026
Quando sostenibilità, inclusione e comunità si incontrano, il cambiamento diventa concreto. Nei giorni scorsi un gruppo di colleghi ha partecipato a una giornata di volontariato aziendale presso Masseria Ferraioli ad Afragola, il più grande bene confiscato alla criminalità organizzata dell'area metropolitana di Napoli, oggi trasformato in un simbolo di legalità, inclusione e agricoltura sostenibile. Un luogo speciale che dimostra come la tutela della biodiversità possa generare valore per le persone e per il territorio, creando opportunità e rafforzando il senso di comunità. Durante la giornata, i partecipanti hanno contribuito ad attività di rigenerazione ambientale e agricoltura sociale, vivendo un'esperienza fatta di collaborazione, condivisione e impegno verso l'ambiente che ci circonda. Questa iniziativa rappresenta concretamente ciò in cui crediamo: una sostenibilità che mette al centro la natura, le persone e le comunità locali. Perché il cambiamento più duraturo nasce quando crescita, inclusione e sostenibilità procedono insieme. Un sentito ringraziamento al nostro partner Treedom, che ha reso possibile questa esperienza, e a Masseria Ferraioli per l'accoglienza e per il lavoro straordinario che porta avanti ogni giorno. La collaborazione tra realtà diverse, unite da valori comuni e da una visione condivisa, dimostra come sia possibile generare un impatto positivo e duraturo per l'ambiente, le persone e le comunità. Naturally Together. 🌱 #UDiversity #NaturallyTogether #Volunteering #Sustainability #ESG #Inclusion #Biodiversity #SocialImpact #CommunityEngagement
- Dr. Vince Clinical ResearchSince 26 Oct 2026
Maintain continuity from your first protocol draft through the final report. Work with one team to streamline trial timelines and make faster, more informed decisions for your study.
- Dr. Vince Clinical ResearchSince 26 Oct 2026
Reach your clinical milestones faster with end-to-end support from Phase I through III. Explore the range of studies DVCR manages across different therapeutic areas and trial designs.
- Excent TandtechniekSince 26 Oct 2026
Een tandtechnisch laboratorium moet meer zijn dan een plek waar u werk naartoe stuurt. Goede tandtechniek draait om kwaliteit, maar ook om persoonlijk contact, heldere communicatie en een samenwerking waarop u kunt vertrouwen. Bij Excent combineren we de kennis en mogelijkheden van een grote tandtechnische organisatie met persoonlijke ondersteuning vanuit onze laboratoria. Vanuit Excent Veenendaal en Excent Gouda helpen we ook tandartspraktijken in de regio Zeist. Benieuwd of Excent bij uw praktijk past? Laat uw gegevens achter. We brengen u graag in contact met het laboratorium dat het beste bij u past.
- CompuGroup Medical FranceSince 25 Oct 2026
💊 Une aide à la prescription fiable, directement intégrée à votre logiciel médical. Interactions médicamenteuses, contre-indications, posologies : avec Libellia et sa base Thériaque, bénéficiez d'une aide à la prescription certifiée LAP V2 pour accompagner vos décisions au quotidien. 👉 Découvrez Libellia dès 89 €/mois avec notre offre de lancement.
- CompuGroup Medical FranceSince 25 Oct 2026
🩺 Médecins généralistes, et si votre logiciel médical vous simplifiait vraiment la vie ? Moins de temps consacré à l'administratif, plus de temps pour vos patients. Découvrez Libellia, le logiciel médical conçu pour faciliter votre quotidien au cabinet. 👉 Découvrez notre offre de lancement à partir de 89 €/mois.
Other LinkedIn formats
Watch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.